Saturday 17 October 2026 Export ORIC’s income statement to Excel — free account

Oric Pharmaceuticals, Inc.

In the quarter to June 2026, EPS grew 19.2% and free cash flow fell 3.42%, each against the same quarter a year earlier.

12.35 0.42 −3.29%

Follow ORIC

Alert me

Market cap: $1.3B
P/E: 0.0×
Fwd P/E: —
Dividend yield: —
F-score: n/a
Altman Z: n/a
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 2.77

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	3	1	1	—	—	—	—	2	1	2	1

Insider Ownership 36.85%

Capital & Financial Ratios $m

Market Cap 1,320.00

Revenue —

Net Income (140.35)

Free Cash Flow (112.26)

Net Debt (264.76)

Current Ratio 13.19

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E —

P/S ratio 0.00

P/B ratio 3.50

Past 5Y EPS Growth —

This Y EPS Growth (2.27%)

Next Y EPS Growth (10.55%)

Next Y revenue growth —

Next 5Y EPS Growth (6.73%)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

P/B against its own 10 years 92.80%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2019	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	208	256	281	265
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	—	—	—	—
	213	262	288	274

	2023	2024	2025	Q'26
Payables	1	2	4	4
ST’ Debt	—	—	—	—
Other	—	—	—	—
	20	25	20	21

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	—
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	5.81%	20.01%

Revenue $m

	Year

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(32)	(32)	—	—	—
’25	(33)	(31)	(25)	(22)	(111)
’24	(30)	(26)	(29)	(28)	(113)
’23	(21)	(21)	(20)	(24)	(86)
’22	(23)	(18)	(19)	(15)	(75)
’21	(15)	(16)	(12)	(16)	(60)
’20	(8)	(10)	(10)	(18)	(45)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(32)	(32)	—	—	—
’25	(33)	(31)	(25)	(23)	(112)
’24	(30)	(26)	(29)	(28)	(114)
’23	(21)	(22)	(20)	(24)	(87)
’22	(23)	(18)	(20)	(16)	(77)
’21	(15)	(16)	(12)	(17)	(60)
’20	(8)	(10)	(10)	(18)	(46)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.34)	(0.38)	—	—	—
’25	(0.42)	(0.47)	(0.33)	(0.30)	(1.47)
’24	(0.37)	(0.45)	(0.49)	(0.51)	(1.83)
’23	(0.53)	(0.50)	(0.44)	(0.49)	(1.96)
’22	(0.59)	(0.51)	(0.63)	(0.52)	(2.25)
’21	(0.45)	(0.57)	(0.47)	(0.58)	(2.07)
’20	(4.46)	(0.51)	(0.84)	(0.84)	(3.36)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	18.60	11.28	2.36	4.09	6.33	3.90	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	40.81	39.45	16.76	9.79	16.65	14.93
People
People	Employees	—	—	—	57	61	78	86	100	115	104
	Revenue/emp, $m	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Income, $m
Income, $m	Revenue	—	—	—	—	—	—	—	—	—	—
	Gross margin, %	—	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—
	EBT	—	(22)	(21)	(27)	(74)	(79)	(89)	(101)	(128)	(129)
	EBT margin, %	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Net income	—	0	(21)	(27)	(74)	(79)	(89)	(101)	(128)	(129)
	Depreciation	—	1	1	1	1	2	0	(5)	(7)	(1)
Per share, $
Per share, $	Revenue	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Earnings	—	(0.74)	(12.32)	(14.16)	(3.36)	(2.07)	(2.25)	(1.96)	(1.83)	(1.47)
	Cash flow	—	(0.70)	(11.93)	(12.39)	(2.06)	(1.57)	(1.89)	(1.67)	(1.62)	(1.26)
	Capex	—	0.00	(0.30)	(0.40)	(0.03)	(0.02)	(0.05)	(0.02)	(0.02)	(0.01)
	Free cash flow	—	(0.70)	(12.23)	(12.80)	(2.09)	(1.59)	(1.95)	(1.68)	(1.63)	(1.27)
	Book value	—	0.86	0.00	(47.44)	13.21	7.19	5.61	4.36	3.49	4.38
	Shares, m	—	30	2	2	22	38	40	51	70	88
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	—	—	—	—	—
	P/S	—	—	—	—	—	—	—	—	—	—
	P/B	—	—	—	—	—	—	—	—	—	—
	EV/Sales	—	—	—	—	—	—	—	—	—	—
	EV/FCF	—	—	—	—	—	—	—	—	—	—
Cash, $m
Cash, $m	Operating cash flow	—	(21)	(21)	(24)	(45)	(60)	(75)	(86)	(113)	(111)
	Capex	—	0	(1)	(1)	(1)	(1)	(2)	(1)	(1)	(1)
	Free cash flow	—	(21)	(21)	(24)	(46)	(60)	(77)	(87)	(114)	(112)
Balance, $m
Balance, $m	Working capital	—	24	41	85	288	225	195	192	237	268
	Total debt	—	—	—	—	—	12	12	—	—	—
	Net debt	—	(26)	(43)	(89)	(294)	(237)	(206)	(208)	(256)	(281)
	Shareholders’ equity	—	26	—	(90)	290	273	222	224	243	384
Returns, %
Returns, %	ROA	—	(57.40)	0.00	(57.14)	(37.50)	(26.34)	(32.66)	(40.34)	(48.60)	(37.91)
	ROIC	—	0.00	0.00	0.00	0.00	(136.94)	(356.70)	(435.43)	0.00	(86.88)
	ROE	—	40.78	39.55	34.80	(73.82)	(27.98)	(35.99)	(45.11)	(54.73)	(41.27)

Negative figures in brackets.

All 10 years →

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
RAPP Rapport Therapeutics, Inc.	$1.4B	— (loss-making)	—	—	n/m	−64.75% (below 0%: shrinking)	100.00%	0.00%	Compare
AAPG Ascentage Pharma Group International - Unsponsored ADR	$1.4B	—	—	—	—	+17.74% (above 0%: growing)	—	—	Compare
OMER Omeros Corporation	$1.4B	9.5×	2.1×	+35.46% (above 0%: growing)	n/m	+118.70% (above 0%: growing)	97.20%	0.26%	Compare
INBX Inhibrx Biosciences, Inc.	$1.3B	— (loss-making)	— (loss-making)	+992.44% (above 0%: growing)	n/m	+0.12% (above 0%: growing)	100.00%	0.00%	Compare
ORIC Oric Pharmaceuticals, Inc.	$1.3B	— (loss-making)	—	—	n/m	−3.42% (below 0%: shrinking)	0.00%	0.00%
TYRA Tyra Biosciences, Inc.	$1.3B	— (loss-making)	—	—	n/m	−31.34% (below 0%: shrinking)	0.00%	0.00%	Compare
GHRS GH Research PLC	$1.3B	— (loss-making)	—	—	n/m	−66.62% (below 0%: shrinking)	0.00%	0.00%	Compare
NKTR Nektar Therapeutics	$1.3B	— (loss-making)	— (loss-making)	−9.34% (below 0%: shrinking)	n/m	−65.73% (below 0%: shrinking)	100.00%	(417.94%)	Compare
DRTS Alpha Tau Medical Ltd.	$1.2B	— (loss-making)	—	—	n/m	−30.42% (below 0%: shrinking)	0.00%	0.00%	Compare
Median of peers	$1.3B	—	—	+35.46%	—	−30.88%	97.20%	0.00%

All 614 Biotechnology stocks →

Oric Pharmaceuticals, Inc. (ORIC) key facts

Oric Pharmaceuticals, Inc. (ORIC) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, ORIC traded at $12.35, a market capitalization of $1.3 billion.
Return on equity was −41.3% and debt-to-equity 0.00.

Source: company filings (standardised) and stockrow calculations.